Skip to main content
SNSE
NASDAQ Life Sciences

Sensei Biotherapeutics Appoints President/CEO and Experienced Biotech CFO to Board

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$9.09
Mkt Cap
$11.465M
52W Low
$5
52W High
$18.35
52W Position info
82% above low
Off High info
50% below high
Rel. Volume
Market data snapshot near publication time

SNSE sits 82% above its 52-week low of $5.

Summary

Sensei Biotherapeutics, Inc. expanded its board from three to five members, appointing its President and Principal Executive Officer, Christopher W. Gerry, and seasoned biotech finance executive, Phillip B. Donenberg, as new directors.


Key Events · Executive and Board Changes · SNSE

  • Board Expansion

    The board of directors increased its size from three members to five members, effective immediately.

  • Internal Leadership Appointment

    Christopher W. Gerry, the company's President, Principal Executive Officer, and General Counsel, was appointed to the board of directors.

  • Experienced Independent Director Appointed

    Phillip B. Donenberg, a Certified Public Accountant with extensive experience as a CFO and audit committee chairman for other public biotech companies, was appointed as a new independent director.

  • Enhanced Governance

    Mr. Donenberg's appointment is expected to strengthen the board's financial oversight and strategic guidance, which is particularly beneficial for a micro-cap company.


Analysis · SNSE · Life Sciences

The expansion of Sensei Biotherapeutics' board and the appointment of two new directors, including its current President and an experienced independent financial expert, signals a move to strengthen corporate governance and strategic oversight. For a micro-cap company, adding a director with Phillip B. Donenberg's background in finance and audit committees from other public biotech firms is particularly valuable, potentially enhancing financial stewardship and investor confidence. The appointment of the current President, Christopher W. Gerry, to the board is a logical step to align executive leadership with board-level decision-making.

At the time of this filing, SNSE was trading at $9.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.5M. The 52-week trading range was $5.00 to $18.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SNSE - Latest Insights

SNSE
Jun 26, 2026, 7:40 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $13.85
Real-time Price: $13.85 info
Change: $0 (0%) info
Market Cap: $18.586M info
SNSE
Jun 24, 2026, 6:58 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $13.85
Real-time Price: $13.85 info
Change: $0 (0%) info
Market Cap: $18.586M info
SNSE
Jun 24, 2026, 6:55 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $13.85
Real-time Price: $13.85 info
Change: $0 (0%) info
Market Cap: $18.586M info
SNSE
Jun 18, 2026, 5:13 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $13.85
Real-time Price: $13.85 info
Change: $0 (0%) info
Market Cap: $18.586M info
SNSE
Jun 18, 2026, 4:01 PM EDT
Filing Type: S-3ASR
Importance Score:
9
Price at Filing: $13.85
Real-time Price: $13.85 info
Change: $0 (0%) info
Market Cap: $18.586M info